BR112017015631A2 - célula t exterminadora universal - Google Patents
célula t exterminadora universalInfo
- Publication number
- BR112017015631A2 BR112017015631A2 BR112017015631A BR112017015631A BR112017015631A2 BR 112017015631 A2 BR112017015631 A2 BR 112017015631A2 BR 112017015631 A BR112017015631 A BR 112017015631A BR 112017015631 A BR112017015631 A BR 112017015631A BR 112017015631 A2 BR112017015631 A2 BR 112017015631A2
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- modified
- universal
- immunogenic
- tcr
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 abstract 7
- 230000002163 immunogen Effects 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46443—Growth factors
- A61K39/464434—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
a presente invenção refere-se a uma célula exterminadora natural modificada (nk) e seu uso na medicina personalizada. as células nk modificadas da presente invenção são não-imunogênicas, o que significa que elas podem ser administradas a qualquer sujeito receptor sem serem rejeitadas pelo sistema imune do hospedeiro (elas são "universais"). em uma primeira modalidade, as células nk não-imunogênicas são modificadas para expressar cd3 para permitir que um receptor de células t (tcr) seja expresso. em outra modalidade, as células nk não-imunogênicas são ainda modificadas para expressar um tcr juntamente com o correceptor cd3. a coexpressão de cd3 com um tcr específico resulta nas células nk modificadas que mostram citotoxicidade antígeno-específica em relação às células alvo. assim, as células nk universais podem ser direcionadas contra antígenos específicos e podem, portanto, ser usadas em medicina personalizada, particularmente no campo da oncologia.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1501175.2 | 2015-01-23 | ||
| GBGB1501175.2A GB201501175D0 (en) | 2015-01-23 | 2015-01-23 | A universal T-cell for personalised medicine |
| PCT/EP2016/051344 WO2016116601A1 (en) | 2015-01-23 | 2016-01-22 | Universal killer t-cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017015631A2 true BR112017015631A2 (pt) | 2018-03-13 |
| BR112017015631B1 BR112017015631B1 (pt) | 2023-08-22 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| IL253464A0 (en) | 2017-09-28 |
| EP3247791B1 (en) | 2022-05-04 |
| US20220127574A1 (en) | 2022-04-28 |
| NZ733855A (en) | 2023-10-27 |
| GB201501175D0 (en) | 2015-03-11 |
| AU2016208475B2 (en) | 2021-10-14 |
| AU2016208475A1 (en) | 2017-08-03 |
| US20180010097A1 (en) | 2018-01-11 |
| MX2017009459A (es) | 2018-04-11 |
| PL3247791T3 (pl) | 2022-09-05 |
| KR20170121178A (ko) | 2017-11-01 |
| DK3247791T3 (da) | 2022-07-11 |
| CA2973924A1 (en) | 2016-07-28 |
| CN107250351A (zh) | 2017-10-13 |
| EP3247791A1 (en) | 2017-11-29 |
| ES2922231T3 (es) | 2022-09-12 |
| SG11201705693XA (en) | 2017-08-30 |
| JP2018512047A (ja) | 2018-05-10 |
| EA201791381A1 (ru) | 2018-02-28 |
| IL253464B (en) | 2022-04-01 |
| JP6899333B2 (ja) | 2021-07-07 |
| WO2016116601A1 (en) | 2016-07-28 |
| US11155786B2 (en) | 2021-10-26 |
| PT3247791T (pt) | 2022-07-20 |
| CA2973924C (en) | 2024-06-04 |
| KR102479118B1 (ko) | 2022-12-16 |
| AU2022200126A1 (en) | 2022-02-10 |
| EP4095239A1 (en) | 2022-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791381A1 (ru) | Универсальная клетка т-киллер | |
| BR112019018863A8 (pt) | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos | |
| AR127117A2 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores | |
| CO2018005945A2 (es) | Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este | |
| CO2017003408A2 (es) | Anticuerpos y fragmentos de los mismos como agonistas de gitr | |
| AU2017259987A1 (en) | Intracellular delivery of biomolecules to induce tolerance | |
| UA120948C2 (uk) | Заміщені індазоли, способи їх одержання, фармацевтичні препарати, які їх містять, та їх застосування для одержання лікарських засобів | |
| BR122021000068A8 (pt) | Composições e usos em métodos para estimular a eficácia de imunoterapia celular adotiva | |
| CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
| CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
| BR122020002988A8 (pt) | Método e composições para imunoterapia celular | |
| BR112016023513A2 (pt) | expressão de transgene relacionada com fármacos | |
| BR112016006122A2 (pt) | composições imunogênicas e métodos com coronavírus da síndrome respiratória do oriente médio (mers-cov) | |
| BR112017027876A2 (pt) | ?sistema de distribuição, método de preparação do sistema de distribuição e composição? | |
| BR112016014293A2 (pt) | região de fragmento cristalizável canino, anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, e, método para aumentar a atividade de uma célula imune | |
| BR112019011065A2 (pt) | métodos para determinação da dosagem de células t car | |
| CR20180040A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia y métodos para crear soportes para el uso contra el cáncer de páncreas y otros tipo de cáncer. | |
| EA201891124A2 (ru) | Новые мукозные адъюванты и системы доставки | |
| BR112015023886A2 (pt) | polipeptídeo, ácido nucleico, composição farmacêutica, e, método | |
| BR112018006006A2 (pt) | receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica | |
| CO2017009922A2 (es) | Péptidos y combinación de péptidos para inmunoterapia contra diversos tumores | |
| PH12018502278A1 (en) | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies | |
| CL2021001010A1 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer (divisional de la solicitud no. 201800780) | |
| CO2017009101A2 (es) | Péptidos y combinación de péptidos | |
| Feodrippe et al. | Medical students' quality of life: a review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/01/2016, OBSERVADAS AS CONDICOES LEGAIS |